We are pleased to announce a new with Dr. David Plat, CEO of , Inc. – Publicly traded under the symbol:


BTHECLICK HERE TO LISTEN TO BOSTON THERAPEUTICS’ FIRST INTERVIEW

Interviewee: Dr.
Company: Boston Therapeutics, Inc.
Trading Symbol: BTHE
Website: http://www.bostonti.com/

ABOUT DR. DAVID PLATT

Dr David PlattChairman, Chief Executive Officer, Interim Chief Financial Officer and Director

Dr. Platt, our President from the inception of the Company in August 2009 through November 2010. From 2001 toFebruary 2009, Dr. Platt was Chief Executive Officer and Chairman of the Board of Directors of Pro-Pharmaceuticals, Inc., a public company with shares traded on the NYSE Alternext US (formerly the American Stock Exchange) that he co-founded and for which he was the co-developer of their core technology. From 1995 to 2000, Dr. Platt was Chief Executive Officer and Chairman of the Board of Directors of SafeScience Inc., a Nasdaq-listed company he founded. From 1992 to 1995, Dr. Platt was the Chief Executive Officer, Chairman of the Board and a founder of International Gene Group, Inc., the predecessor company to SafeScience. Dr. Platt received a Ph.D. in Chemistry in 1988 from Hebrew University in Jerusalem. In 1989, Dr. Platt was a research fellow at the Weizmann Institute of Science, Rehovot, Israel, and from 1989 to 1991, was a research fellow at the Michigan Foundation (re-named Barbara Ann Karmanos Institute). From 1991 to 1992, Dr. Platt was a research scientist with the Department of Internal Medicine at the University of Michigan. Dr. Platt has published peer-reviewed articles and holds many patents, primarily in the field of carbohydrate chemistry.

ABOUT BOSTON THERAPEUTICS, INC.

Boston Therapeutics, Inc. (OTCQB: BTHE) is a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes.

The Company’s initial product pipeline is focused on developing and commercializing therapeutic molecules:

BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. BTI-320 inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion, reducing the amount of available glucose absorbed through the intestine.

IPOXYN™ is a glyco-protein based therapeutic agent using proprietary processes and patented technology. IPOXYN™ is an anti-necrosis drug that consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.

OXYFEX™ can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events.

Tags

 
 
 
 

Enjoy this site? Please spread the word :)

RSS
EMAIL
SHARE